Literature DB >> 30788497

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

B Escudier1, C Porta2, M Schmidinger3, N Rioux-Leclercq4, A Bex5, V Khoo6, V Grünwald7, S Gillessen8, A Horwich9.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30788497     DOI： 10.1093/annonc/mdz056

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  181 in total

1.  The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.

Authors:  Angelina Tjokrowidjaja; David Goldstein; H Malcolm Hudson; Sarah J Lord; Val Gebski; Stephen Clarke; Paul de Souza; Robert J Motzer; Chee Khoon Lee
Journal:  Acta Oncol       Date:  2019-08-29       Impact factor: 4.089

2.  Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.

Authors:  Yasuhiro Iribe; Mitsuko Furuya; Yousuke Shibata; Masato Yasui; Makoto Funahashi; Junichi Ota; Hiromichi Iwashita; Yoji Nagashima; Hisashi Hasumi; Narihiko Hayashi; Kazuhide Makiyama; Keiichi Kondo; Reiko Tanaka; Masahiro Yao; Noboru Nakaigawa
Journal:  Fam Cancer       Date:  2020-07-15       Impact factor: 2.375

3.  A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma.

Authors:  Christian Kollmannsberger; Toni K Choueiri; Daniel Y C Heng; Saby George; Fei Jie; Ruslan Croitoru; Srinivasu Poondru; John A Thompson
Journal:  Oncologist       Date:  2021-01-19

4.  Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?

Authors:  Eugenia Y Lee; Andrew T Yan
Journal:  Ann Transl Med       Date:  2019-07

5.  To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitoris necessary in the treatment of advanced or metastatic renal cell carcinoma.

Authors:  Leitao Sun; Leyin Zhang; Jieru Yu; Yiwen Zhou; Chao Shi; Harpreet S Wasan; Shanming Ruan; Dawei Huang
Journal:  Med Oncol       Date:  2020-02-01       Impact factor: 3.064

6.  Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?

Authors:  G Marvaso; G Corrao; O Oneta; M Pepa; M Zaffaroni; F Corso; S Gandini; A Cecconi; D Zerini; G C Mazzola; M Augugliaro; M Cossu Rocca; E Verri; F Cattani; F La Fauci; L Bergamaschi; S Luzzago; A F Mistretta; G Musi; F Nolè; O De Cobelli; R Orecchia; B A Jereczek-Fossa
Journal:  Clin Transl Oncol       Date:  2021-03-09       Impact factor: 3.405

7.  Vaginal bleeding as primary presentation of renal cell carcinoma.

Authors:  Asaad Moradi; Behnam Shakiba; Robab Maghsoudi; Reza Dehghaniathar
Journal:  CEN Case Rep       Date:  2020-01-08

8.  The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.

Authors:  Elie Rassy; Luigi Cerbone; Edouard Auclin; Axelle Benchimoll-Zouari; Ronan Flippot; Carolina Alves Costa Silva; Emeline Colomba; Arthur Geraud; Annalisa Guida; Olivier Mir; David Combarel; Angelo Paci; Bernard Escudier; Laurence Albiges
Journal:  Oncologist       Date:  2021-02-25

9.  The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.

Authors:  Lana Hamieh; Rachel L Beck; Valerie H Le; James J Hsieh
Journal:  Clin Genitourin Cancer       Date:  2020-03-14       Impact factor: 2.872

10.  Controlled ovarian stimulation therapy as a potential risk for the development and progression of renal cell carcinomas: A case report and literature review.

Authors:  Sotirios G Doukas; Boris Martinez; Marnie E Rosenthal; Dimitra P Vageli
Journal:  Mol Clin Oncol       Date:  2021-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.